Clinical Trial Update: Effect of Thiazolidinedione Treatment Vascular Risk Markers [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of thiazolidinedione treatment on vascular risk markers in type 2 diabetes patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus
• Vascular Diseases

Drugs mentioned

• Thiazolidinedione (thiazolidinedione)

Snippet

Sponsor: University of Arkansas | Conditions: Diabetes Mellitus, Type 2, Vascular Diseases | Phase 4 | Status: COMPLETED